LBA102 THOR-2 cohort 1: Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients (pts) with high-risk non–muscle-invasive bladder cancer (HR NMIBC) with select fibroblast growth factor receptor alterations (FGFRALT) who received prior bacillus calmette-guérin (BCG) treatment

J.W.F Catto,V Guadalupi,J.E Gschwend,G.D Steinberg,B Tran,S Triantos,S Daneshmand,N Vasdev,L Crow,G Procopio,V Naini,J Palou,H Nishiyama,H.J Cutuli,S.A Hussain,M Roupret,Y Loriot,M Baig

doi:10.1016/j.annonc.2023.10.108

LBA102 THOR-2 cohort 1: Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients (pts) with high-risk non–muscle-invasive bladder cancer (HR NMIBC) with select fibroblast growth factor receptor alterations (FGFRALT) who received prior bacillus calmette-guérin (BCG) treatment

J.W.F Catto, V Guadalupi + Show 16 more

https://doi.org/10.1016/j.annonc.2023.10.108

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Publication Date: Oct 1, 2023

#Fibroblast Growth Factor Receptor Alterations #Muscle-invasive Bladder Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

LBA102 THOR-2 cohort 1: Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients (pts) with high-risk non–muscle-invasive bladder cancer (HR NMIBC) with select fibroblast growth factor receptor alterations (FGFRALT) who received prior bacillus calmette-guérin (BCG) treatment

Full Text